Physicians' Academy for Cardiovascular Education

Higher cholesterol variability associated with increased incidence of CV outcomes

Jan. 8, 2018 - Kim MK, et al. - Eur Heart J 2017

In a large population-based cohort study, cholesterol variability was an independent predictor for the development of MI and stroke, as well as for all-cause mortality, in the general population.

Time to better counteract the anti-statin lobby, to prevent unnecessary harm to patients

Jan. 4, 2018 - news

Following a TV program on the French-German public network ARTE that denied the proven link between cholesterol levels and CVD, the potential effects of such disinformation are considered.

Novel method to calculate LDL-c beats Friedewald formula in both fasting and non-fasting samples

Jan. 4, 2018

The method is an adaptation of the Friedwald formula that incorporates a patient-specific TG:VLDL-ratio. Added accuracy is largest in those with LDL-c <70 mg/dL, without added expense.

There is hope for treatment of HFpEF

Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore
Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.

Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.

DASH diet combined with low sodium intake leads to greater BP-lowering in patients with higher baseline level

Dec. 18, 2017 - Juraschek SP, et al. - J Am Coll Cardiol 2017

The combination of low sodium intake and the DASH diet was associated with significant SBP reductions in patients with a higher baseline level compared with normal diet plus high sodium.

Fewer ventricular arrhythmias with angiotensin-neprilysin vs angiotensin inhibition in HF

Dec. 18, 2017 - de Diego C et al. - Heart Rhythm 2017

In HFrEF patients with an ICD under remote control, treatment with ARNI decreased ventricular arrhythmias and appropriate ICD shocks as compared to angiotensin inhibition alone.

Staggering results for weight reduction in T2DM

IDF 2017 - Abu Dhabi, UAE

Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK
**IDF 2017** Prof Sattar reports on the results of the DIRECT trial evaluating the intervention with a weight management program with huge implications for clinical practice. Almost 75% of the patients in the intervention group had a weight loss >10 kg and half of the patients in this group had remission of diabetes after 1 year of the start of the trial.

IDF 2017 Prof Sattar reports on the results of the DiRECT trial evaluating a weight management program with huge implications for clinical practice. Almost half of the patients in the intervention group had remission of T2DM 1 year after the start of the trial.

Are the COMPASS trial results applicable on a broader population in the REACH registry?

Dec. 14, 2017 - Darmon A, et al. - Eur Heart J 2017

COMPASS-eligible patients represented a substantial fraction of the spectrum of stable CAD and PAD outpatients from the REACH registry.

Midlife systemic inflammation may promote the development of white matter dysfunction

Dec. 13, 2017 - Walker KA, et al. - Stroke 2017

In a sub-analysis of the ARIC study, midlife systemic inflammation was associated with the development of chronic microangiopathic structural white matter abnormalities in the elderly.

Release of ADA 2018 Standards with new recommendations for diabetes patients with CVD

Dec. 12, 2017 - news

Notably, new recommendations in the 2018 edition of the ADA Standards of Care reflect advances in diabetes treatment with antidiabetic drugs with CV benefit.

GLP-1 receptor agonist approved by FDA for treatment of T2DM

Dec. 12, 2017 - news

Based on the results of the SUSTAIN trial, semaglutide is approved by the FDA for the treatment of T2DM patients.

First time randomized trial shows remission of T2DM with dietary and lifestyle intervention

Dec. 11, 2017 - Lean MEJ et al., - The Lancet, 2017
The DIRECT trial evaluated a weight management program delivered by primary care. On average, weight reduced by 10 kg and almost half achieved and maintained remission of T2DM at 12 months after starting the intervention.

The DIRECT trial evaluated a weight management program delivered by primary care. On average, weight reduced by 10 kg and almost half achieved and maintained remission of T2DM at 12 months after starting the intervention.

Agenda